- Home
- HBIO vs BCTX Comparison
HBIO vs BCTX Comparison
Compare HBIO & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- BCTX
- Stock Information
- Founded
- HBIO 1901
- BCTX 2014
- Country
- HBIO United States
- BCTX Canada
- Employees
- HBIO N/A
- BCTX N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- BCTX Health Care
- Exchange
- HBIO Nasdaq
- BCTX Nasdaq
- Market Cap
- HBIO 19.6M
- BCTX 23.5M
- IPO Year
- HBIO 2000
- BCTX N/A
- Fundamental
- Price
- HBIO $0.45
- BCTX $0.80
- Analyst Decision
- HBIO Buy
- BCTX Strong Buy
- Analyst Count
- HBIO 2
- BCTX 1
- Target Price
- HBIO $3.00
- BCTX $32.00
- AVG Volume (30 Days)
- HBIO 1.2M
- BCTX 2.4M
- Earning Date
- HBIO 08-11-2025
- BCTX 06-16-2025
- Dividend Yield
- HBIO N/A
- BCTX N/A
- EPS Growth
- HBIO N/A
- BCTX N/A
- EPS
- HBIO N/A
- BCTX N/A
- Revenue
- HBIO $91,397,000.00
- BCTX N/A
- Revenue This Year
- HBIO N/A
- BCTX N/A
- Revenue Next Year
- HBIO $9.75
- BCTX N/A
- P/E Ratio
- HBIO N/A
- BCTX N/A
- Revenue Growth
- HBIO N/A
- BCTX N/A
- 52 Week Low
- HBIO $0.28
- BCTX $0.69
- 52 Week High
- HBIO $3.48
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- HBIO 49.68
- BCTX 14.49
- Support Level
- HBIO $0.39
- BCTX $0.79
- Resistance Level
- HBIO $0.48
- BCTX $3.00
- Average True Range (ATR)
- HBIO 0.03
- BCTX 0.22
- MACD
- HBIO -0.00
- BCTX -0.20
- Stochastic Oscillator
- HBIO 67.67
- BCTX 5.51
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.